Medgenics, Inc. Comments on Market Trading Activity
4/27/2012 9:56:31 AM
MISGAV, Israel and SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that the NYSE Amex contacted the Company and, in accordance with its usual practice, requested that the Company issue a press release regarding the increased activity in the trading of its common stock. Medgenics states that as a matter of policy, the Company does not comment on unusual market activity or rumors.